Quantum BioPharma (QNTM) announced that Rodman & Renshaw has initiated analyst coverage with a BUY rating and a US$8 price target.
Quantum BioPharma (QNTM) announced that Rodman & Renshaw has initiated analyst coverage with a BUY rating and a US$8 price target.
The initiation research report is led by Michael G. King Jr., Director of Research and Senior Biotechnology Analyst at Rodman & Renshaw. The company states that the coverage is unpaid, with Quantum BioPharma providing no consideration or fees for the report. A copy of the initiation report is available through the referenced “Quantum Published Initiation Report.”
Loading…
Loading translation…
Positive
- Rodman & Renshaw BUY rating with a US$8 price target on QNTM
- Equity research coverage is unpaid, with no fees or consideration to Rodman & Renshaw
- Price Target
- US$8
- Rodman & Renshaw analyst coverage initiation
price target financial
“with a BUY rating and a US$8 price target.”
A price target is an analyst’s estimate of the future value of a stock, typically expressed as a single number for a set time frame. It matters to investors because it acts like an expected selling price when appraising a house—helping people decide whether a stock looks cheap, fairly priced, or expensive compared with current market price and guiding buy, hold or sell decisions; it is an opinion, not a guarantee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces Rodman & Renshaw has initiated coverage of Quantum BioPharma with a BUY rating and a US
Rodman & Renshaw published an initiation research report regarding Quantum BioPharma. The company did not pay Rodman & Renshaw any fees for this report.
A copy of this report can be found at: Quantum Published Initiation Report
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of
For more information visit www.quantumbiopharma.com.
About Rodman & Renshaw
Rodman & Renshaw (“Rodman”) is a full-service Investment Bank with a rich heritage spanning over 70 years. Rodman has deep rooted experience as a leading investment bank, fostering the long-term success of growth companies through Investment Banking, Equity Research, Corporate Access, and Strategic Advisory.
For more information visit www.rodm.com
Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by words such as “may,” “will,” “could,” “should,” “would,” “anticipate,” “expect,” “intend,” “plan,” “believe,” “estimate,” “potential,” “continue,” and similar expressions, although not all forward-looking statements contain these identifying words. These statements are based on the Company’s current expectations, estimates, assumptions and projections and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.
Forward-looking statements in this press release should be considered in light of the risks and uncertainties described in the Company’s filings with applicable securities regulators, including its filings on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts:
Investor Relations
Robert Guzman, Investor Relations
Email: Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries: info@QuantumBioPharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the lead analyst on Rodman & Renshaw’s Quantum BioPharma report?
The initiation report on Quantum BioPharma is led by Michael G. King Jr., who is Director of Research and Senior Biotechnology Analyst at Rodman & Renshaw.
Did Quantum BioPharma pay Rodman & Renshaw for this research coverage?
Quantum BioPharma states that the coverage is unpaid. The company provided no consideration and did not pay Rodman & Renshaw any fees for this initiation research report.
Where can investors access the Rodman & Renshaw initiation report on Quantum BioPharma?
A copy of the Rodman & Renshaw initiation research report on Quantum BioPharma can be found at the referenced link titled “Quantum Published Initiation Report.”
